Olivia M Dong

List of Publications by Year
in descending order

17	169	1163117 8	1125743 13
papers	citations	h-index	g-index

17	17	17	269
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	CYP2C19-guided antiplatelet therapy: a costâ€“effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. Pharmacogenomics, 2017, 18, 1155-1166.	1.3	31
2	Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. Value in Health, 2020, 23, 61-73.	0.3	30
3	Implementing Clinical Pharmacogenomics in the Classroom: Student Pharmacist Impressions of an Educational Intervention Including Personal Genotyping. Pharmacy (Basel, Switzerland), 2018, 6, 115.	1.6	18
4	Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program. Pharmacogenomics, 2021, 22, 137-144.	1.3	16
5	Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients. Pharmacogenomics, 2018, 19, 771-782.	1.3	13
6	Strategies to Integrate Genomic Medicine into Clinical Care: Evidence from the IGNITE Network. Journal of Personalized Medicine, 2021, 11, 647.	2.5	13
7	Characterizing the pharmacogenome using molecular inversion probes for targeted next-generation sequencing. Pharmacogenomics, 2019, 20, 1005-1020.	1.3	9
8	Advancing precision medicine in healthcare: addressing implementation challenges to increase pharmacogenetic testing in the clinical setting. Physiological Genomics, 2017, 49, 346-354.	2.3	8
9	A Costâ€“Consequence Analysis of Preemptive SLCO1B1 Testing for Statin Myopathy Risk Compared to Usual Care. Journal of Personalized Medicine, 2021, 11, 1123.	2.5	7
10	Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma. Value in Health, 2022, 25, 582-594.	0.3	6
11	Clinical pharmacogenetics: how do we ensure a favorable future for patients?. Pharmacogenomics, 2018, 19, 553-562.	1.3	5
12	Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites. Pharmacogenomics, 2021, 22, 1121-1133.	1.3	5
13	Challenges and Solutions for Future Pharmacy Practice in the Era of Precision Medicine. American Journal of Pharmaceutical Education, 2018, 82, 6652.	2.1	4
14	Cost-effectiveness ofCYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes. European Heart Journal Quality of Care & Clinical Outcomes, 2023, 9, 249-257.	4.0	3
15	Are We Ready for a New Approach to Comparing Coverage and Reimbursement Policies for Medical Nutrition in Key Markets: An ISPOR Special Interest Group Report. Value in Health, 2022, 25, 677-684.	0.3	1
16	ONE-YEAR COST-EFFECTIVENESS OF CYP2C19- GUIDED DE-ESCALATION AND ESCALATION OF P2Y12 INHIBITORS IN VETERANS WITH ACUTE CORONARY SYNDROMES UNDERGOING PERCUTANEOUS CORONARY INTERVENTION. Journal of the American College of Cardiology, 2021, 77, 3416.	2.8	0
17	Using the Diffusion of Innovation Theory to Understand the Challenges and Opportunities to Advancing Use of Nutrigenetics in Clinical Practice. Lifestyle Genomics, 2021, 14, 1-5.	1.7	0